ALZHEIMER'S disease (AD) has been extremely elusive to treat but a new randomised, double-blind controlled trial published in Frontiers in Aging Neuroscience has described a 12 week 60-patient study where probiotics have supported cognitive function and metabolic statuses in these people.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 15 Nov 16
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Nov 16
